



BDG SYNTHESIS

Certificate of Analysis


BDG Synthesis certifies that this reference material meets or exceeds the specifications stated herein.

Barry Dent

Barry R. Dent, PhD, Director
8 January 2007

Name: Ciprofloxacin-d₈
CAS Number: 85721-33-1 (unlabelled)

Structure:



Molecular Weight: C₁₇H₁₀D₈FN₃O₃ = 339.39
Lot Number: BDG 5539-0
Appearance: Off-white, powder
Corrected Purity: 99.0 % (HPLC) - 0.2 % (acetone) - 0.1 % (acetic acid) - 17.3 % (water) = 81.4 %
Isotopic Purity: Under 0.5 % d₀
Re-test Date: 8 January 2012
Storage and Handling: Temperature: ambient laboratory temperature; may be refrigerated.
Humidity: may be hygroscopic; store desiccated; recommended to determine water content periodically.
Light: protect from strong sunlight.
Caution: only experienced laboratory personnel should handle the material.

Identity and Purity

Proton NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available.

Isotopic Labelling: The small signals observed at the sites of deuteration are present at about 1.7 % of the intensity that would be expected for unlabelled material. This value is within the range specified by the manufacturer (CIL) for the labelled starting material that was used in the synthesis (98% atom D) and we conclude that H/D exchange has not occurred. The signals are most likely to arise from the presence of small amounts of d7 or d6 species. The absence of d0 species as a contributor to these signals was confirmed by HRMS (see below).

Residual Solvents: small amounts of acetic acid (0.1 % w/w) and acetone (0.2 % w/w) are observed.

Impurities: no significant impurities are evident in the spectrum.

Carbon-13 NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available.

Isotopic Labelling: signals at the sites of deuteration have collapsed to small multiplets (as opposed to two sharp singlets that would be expected for unlabelled material), indicating clean deuteration.

High-resolution Mass Spectrum (ESI+)

Found m/z 340.1890. $C_{17}H_{11}D_8FN_3O_3$ $[M+H]^+$ requires m/z 340.1907. The deviation of 5.1 ppm is within normally accepted limits for the establishment of identity by HRMS. No signal for d₀ material was seen (detection limit about 0.5 %).

HPLC

A somewhat broadened, slightly tailing peak is observed (99.0 %). Note: in the absence of reference materials for preparing calibration curves, it is assumed that all peaks have the same detector response. Where possible, the conditions of analysis follow a pharmacopeial or literature method, or have been adapted from same.

Elemental Analysis

	Found:	C 48.67, H 4.63, D 3.89, N 9.93 %
$C_{17}H_{10}D_8FN_3O_3 \cdot 4.5H_2O$	Requires:	C 48.56, H 4.55, D 3.83, N 9.99 %
$C_{17}H_{10}D_8FN_3O_3$	Requires:	C 60.16, H 2.97, D 4.75, N 12.38 %

The elemental analyses fall substantially outside those expected for anhydrous material; the presence of water is reasonably expected from the method of purification and/or the type of material, and the "best-fit" hydrated molecular formula is given.

Karl-Fischer Analysis

	Found:	H ₂ O 17.3 %
$C_{17}H_{10}D_8FN_3O_3 \cdot 4.5H_2O$	Requires:	H ₂ O 19.3 %

Of necessity, only a small sample could be used and only a single or duplicate analysis performed. We are unable to state what the errors in the reported water content are, but recommend that the result be used, as the best available, when determining corrected purity.


The available quantity of custom-synthesised material is always small, and this limits the extent and type of analytical data which can be obtained. This Certificate is presented in descriptive format for use by analytical chemists who are trained in the use of custom-synthesised materials. Custom materials often contain higher levels of residual solvents and/or water, and we urge you to use the corrected purity where needed rather than the raw HPLC purity. This compound is intended for use as an analytical reference material and it is not for human administration. Structures are shown with relative stereochemistry unless otherwise specified.

The re-test date is assigned from experience gained with the material in the laboratory and/or on storage. It is not possible to perform formal storage studies because of the small amount of material available.




Proton NMR Spectrum of Ciprofloxacin-d₈ in DMSO-d₆ + DCI

BDG SYNTHESIS




Lot Number: BDG 5539






Carbon-13 NMR Spectrum of Ciprofloxacin-d₈ in D₂O + DCI

BDG SYNTHESIS




Lot Number: BDG 5539



BDG - Analysis of Ciprofloxacin-d8

Column : Phenomenex Luna C18(2) 5um 250 x 4.6 mm
 Guard : Phenomenex Security Guard C18 RP 4 x 3 mm
 Mobile Phase : 87:13 0.025M H3PO4 pH=3.0 : Acetonitrile
 Flow Rate : 1.5 mL/min
 Sample Solvent : Mobile phase
 Column Temperature : 30C
 Injection Volume : 10 uL
 Detection : UV at 278 nm
 Run Time: 30 mins

Sample Name	BDG 5539	Instrument	AnalyticalLC01
Acquisition	18/12/2006, 21:10:41	Method (rev.)	LC10125a (6)
Sequence	BDG_18Dec2006a - Reprocessed	Vial Position	2
Operator	solvation010\cerityadmin	Injection	2 of 2



Area Percent Report

Peak#	RT	Peak Height	Peak Area	Width	Area %
1	1.97 min	4.0609	20.4149	0.0747 min	0.116 %
2	6.72 min	3.5279	40.5443	0.1761 min	0.230 %
3	8.02 min	0.5794	7.3708	0.1904 min	0.042 %
4	9.65 min	920.1851	17494.1024	0.2918 min	99.030 %
5	11.86 min	5.3746	102.9776	0.2955 min	0.583 %